A Canadian single institution real‐world experience using the CROSS trial regimen in the treatment of Esophageal and Gastroesophageal Junction Carcinoma

2021 ◽  
Author(s):  
S. Khalid ◽  
W.M. Hopman ◽  
K. Virik
Keyword(s):  
Real World ◽  
Gastroesophageal Junction ◽  
Single Institution ◽  
The Cross ◽  
Gastroesophageal Junction Carcinoma

Neoadjuvant chemoradiation (NCRT) for esophageal (EC) or gastroesophageal junction cancer (GEJC): A Canadian single institution real-world experience using the CROSS trial regimen.

2019 ◽  
Vol 37 (27_suppl) ◽  
pp. 25-25
Author(s):  
Sidra Khalid ◽  
Wilma M. Hopman ◽  
Beatrice Preti ◽  
Anna T. Tomiak ◽  
Kiran Virik
Keyword(s):  
Clinical Trial ◽  
Real World ◽  
Gastroesophageal Junction ◽  
Trial Protocol ◽  
Single Institution ◽  
Real World Data ◽  
Trimodality Therapy ◽  
World Data ◽  
The Real ◽  
The Cross

25 Background: NCRT followed by surgery per the CROSS trial regimen is an accepted standard of care in the treatment of EC and GEJC. When treatments are used in the real-world setting, there are often patient, treatment and potential outcome differences compared to the original clinical trial. The study aim was to assess the real-world application and outcomes of the CROSS trial protocol. Methods: A retrospective chart review was undertaken of 83 patients (pts) with EC or GEJC who were treated from June 2012 to June 2018 with CRT. 65 pts were with NCRT intent to proceed to surgery. Pts’ demographics, clinical, pathological, treatment and surgical characteristics were assessed and exploratory analyses were conducted to review these factors and outcomes. Analyses included Chi-square, t-tests and Kaplan-Meier. Results: For pts who underwent NCRT (n = 65): median age was 68 yrs (range 52-80), male 79%, adenocarcinoma 82%, median (m) tumor length 5 cm, GERD 43%, clinical stage II/III 95%, and BMI > 30 in 37%. 80% completed CRT with RT ≥ 41.4 Gy; of these 88% had ≥ 50.4 Gy. Delay/interruption in chemotherapy occurred in 46% and in RT 37%. Pts who underwent surgery were younger (p = 0.04) and weighed more (p = 0.05). mOS was 37 months (M) v 14 M in those who started CRT ≤ 8 weeks (w) from diagnosis v > 8 w (p = 0.10). The median time from CRT to surgery was 8.9 w. 40 pts had surgery with a complete response in 38% and a R0 resection in 98%. Postoperative major and minor complications occurred in 67%. Those < 75 yrs v ≥ 75 yrs had a mOS of 32 M v 15 M respectively (log rank p = 0.46). 25 pts did not get surgery; 28% was due to death/progression. Pts who proceeded to surgery had a mOS of 35 M v 12 M in pts who did not go to surgery (log rank p = 0.002). Further correlative outcome data will be presented. Conclusions: Real-world data in our center showed patient, tumor and treatment differences compared to the CROSS trial protocol. Despite the broadening of eligibility and treatment criteria, survival in a single institution setting is maintained with trimodality therapy compared to NCRT alone. Real-world data is of value in the assessment of therapeutic validity of clinical trial data.

Retrospective comparison of neoadjuvant chemoradiation (nCRT) +/- surgery using the CROSS trial regimen and definitive chemoradiation (dCRT) with carboplatin (C) and paclitaxel (P) in esophageal (EC), and gastroesophageal junction cancer (GEJC) in Canada.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 313-313
Author(s):  
Sidra Khalid ◽  
Wilma M. Hopman ◽  
Kiran Virik
Keyword(s):  
Real World ◽  
Gastroesophageal Junction ◽  
Locally Advanced ◽  
Outcome Data ◽  
World Population ◽  
Trial Protocol ◽  
Real World Data ◽  
Eligibility Criteria ◽  
Trimodality Therapy ◽  
The Cross

313 Background: Trimodality therapy using the CROSS trial protocol is an accepted standard of care for locally advanced EC and GEJC. For medically inoperable patients (pts), CRT has been a standard. CRT with C and P is an option in the definitive setting. This single institution review aims to assess the application and outcomes of the CROSS trial protocol in our real world population. Methods: From June 2012 until June 2018, a retrospective review was undertaken of 83 pts who underwent CRT with C and P with trimodaility or upfront definitive intent. 65 pts underwent nCRT; 40 proceeded to surgery. 18 had upfront dCRT. Pt demographics, clinical, pathological, treatment and surgical characteristics were assessed. These factors and outcomes were analyzed in exploratory analyses. Results: Of the 83 pts: median (m) age was 69 yrs (range 48-82), 34% were ≥ 75 yrs, 80% were male, 21% had CAD, 43% GERD, 23% Barrett’s, 77% adenocarcinoma, m tumor length was 5 cm, 36% had BMI > 30 and 80% were Siewert I tumors. The m RT dose was 50.4 Gy, m chemo doses were 5, m time to CRT was 69 days and m time from CRT to surgery was 66 days. 23% nCRT pts and 72% dCRT pts were ≥ 75 yrs and 49% and 33% of these respectively had no interruptions to CRT. Pts who underwent surgery were younger (p = 0.04) and weighed more (p = 0.05). Pts ≥75 yrs were likely to have dCRT (p = 0.001). For nCRT and surgery, nCRT only and dCRT respectively, median overall survival (mOS) was 35.5, 12.1 and 17.1 months (M) (log rank p = 0.08), PFS was 32.2, 10 and 9.6M (log rank p = 0.01). Compared to the other 2 groups, pts who underwent surgery had: no COPD (p = 0.004), less CAD (p = 0.003), less renal impairment (p = 0.023) and had lower esophageal tumors (p = 0.027). mOS for pts who had nCRT was 28.9M and 17.1M for dCRT (log rank p = 0.70). Further correlative outcome data will be presented. Conclusions: Despite the broadening of CROSS trial eligibility criteria in our real world data, there appears to be a survival benefit with trimodality therapy. The use of C and P in dCRT may be of value especially in the elderly, and requires further study.

ADVANCED INVASIVE LOBULAR CARCINOMA, REAL WORLD EXPERIENCES IN SINGLE INSTITUTION

The Breast ◽  
2019 ◽  
Vol 48 ◽  
pp. S57
Author(s):  
Junichiro Watanabe ◽  
Shogo Nakamoto
Keyword(s):  
Real World ◽  
Invasive Lobular Carcinoma ◽  
Lobular Carcinoma ◽  
Single Institution

Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period

2021 ◽  
Author(s):  
Luis Gerardo Rodríguez‐Lobato ◽  
Arturo Pereira ◽  
Carlos Fernández de Larrea ◽  
Maria Teresa Cibeira ◽  
Natalia Tovar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Single Institution ◽  
Real World Data ◽  
World Data

scholarly journals Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Nuno Cerveira ◽  
Bruno Loureiro ◽  
Susana Bizarro ◽  
Cecília Correia ◽  
Lurdes Torres ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Real World ◽  
Kinase Inhibitors ◽  
Single Institution

scholarly journals Can the CROSS protocol be safely implemented in real world scenario with broader eligibility criteria? Experience from a tertiary care centre in India

2021 ◽  
Vol 15 ◽  
Author(s):  
Tapesh Bhattacharyya ◽  
Moses Arunsingh ◽  
Santam Chakraborty ◽  
Vishnu Harilal ◽  
Rohit Sasidharan ◽  
...  
Keyword(s):  
Real World ◽  
Tertiary Care ◽  
Care Centre ◽  
Tertiary Care Centre ◽  
Eligibility Criteria ◽  
The Cross
Sign in / Sign up

Export Citation Format

Share Document